DexCom, Inc. (NASDAQ:DXCM) Stock Holdings Lessened by Prudential Financial Inc.

Prudential Financial Inc. cut its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 20.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 262,193 shares of the medical device company’s stock after selling 65,414 shares during the period. Prudential Financial Inc.’s holdings in DexCom were worth $20,391,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Versant Capital Management Inc acquired a new stake in shares of DexCom during the 4th quarter valued at $25,000. Private Trust Co. NA raised its holdings in shares of DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after acquiring an additional 245 shares in the last quarter. TD Private Client Wealth LLC boosted its position in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 167 shares during the last quarter. Larson Financial Group LLC grew its stake in DexCom by 40.5% in the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after purchasing an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC acquired a new position in DexCom in the 4th quarter worth about $38,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Down 1.9 %

DXCM opened at $72.13 on Thursday. The business has a 50 day moving average of $82.96 and a 200-day moving average of $77.07. The stock has a market capitalization of $28.19 billion, a price-to-earnings ratio of 50.44, a P/E/G ratio of 2.30 and a beta of 1.28. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $141.99.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, sell-side analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the sale, the chief executive officer now owns 372,029 shares in the company, valued at $26,183,401.02. This represents a 8.03 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 105,009 shares of company stock valued at $8,044,178 over the last three months. 0.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Cfra Research upgraded DexCom to a “hold” rating in a report on Friday, March 21st. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Morgan Stanley increased their price target on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Citigroup lifted their price objective on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Tuesday, March 4th. Finally, Canaccord Genuity Group increased their target price on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and an average target price of $99.82.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.